Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-04-05
2011-04-05
Bunner, Bridget E. (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S142100, C424S143100, C435S326000, C435S334000, C530S388100, C530S388220
Reexamination Certificate
active
07919092
ABSTRACT:
The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
REFERENCES:
patent: 5648464 (1997-07-01), Artavanis-Tsakonas et al.
patent: 5786158 (1998-07-01), Artavanis-Tsakonas et al.
patent: 5789195 (1998-08-01), Artavanis-Tsakonas et al.
patent: 6004528 (1999-12-01), Bergstein
patent: 6083904 (2000-07-01), Artavanis-Tsakonas
patent: 6090922 (2000-07-01), Artavanis-Tsakonas et al.
patent: 6537775 (2003-03-01), Tournier-Lasserve et al.
patent: 6689744 (2004-02-01), Gao et al.
patent: 2002/0122802 (2002-09-01), Wands et al.
patent: 2003/0083465 (2003-05-01), Zimrin et al.
patent: 2003/0186290 (2003-10-01), Tournier-Lasserve et al.
patent: 2005/0112121 (2005-05-01), Artavanis-Tsakonas et al.
patent: 2005/0187179 (2005-08-01), Miele et al.
patent: 2006/0083682 (2006-04-01), Bergstein
patent: 2006/0263774 (2006-11-01), Clark et al.
patent: 2007/0036800 (2007-02-01), Bergstein
patent: 2007/0036801 (2007-02-01), Bergstein
patent: 2007/0036804 (2007-02-01), Bergstein
patent: 2007/0041984 (2007-02-01), Bergstein
patent: 2007/0196047 (2007-08-01), Levner et al.
patent: 2007/0265246 (2007-11-01), Clevers et al.
patent: 2008/0112940 (2008-05-01), Liaw
patent: 2008/0118520 (2008-05-01), Li et al.
patent: 2008/0131434 (2008-06-01), Lewicki et al.
patent: 2008/0131908 (2008-06-01), Li et al.
patent: 2008/0132423 (2008-06-01), Kondo
patent: 2008/0188405 (2008-08-01), Di Fiore et al.
patent: 2008/0226621 (2008-09-01), Fung et al.
patent: 2009/0004205 (2009-01-01), Clarke et al.
patent: WO 97/37004 (1997-10-01), None
patent: WO 97/45143 (1997-12-01), None
patent: WO 98/57621 (1998-12-01), None
patent: WO 00/20576 (2000-04-01), None
patent: WO 00/52143 (2000-09-01), None
patent: WO 02/00576 (2002-01-01), None
patent: WO 02/12447 (2002-02-01), None
patent: WO 02/18544 (2002-03-01), None
patent: WO 03/042246 (2003-05-01), None
patent: WO 03/050502 (2003-06-01), None
patent: WO 03/062273 (2003-07-01), None
patent: WO 2004/001004 (2003-12-01), None
patent: WO 2004/091383 (2004-10-01), None
patent: WO 2005/026334 (2005-03-01), None
patent: WO 2005/054434 (2005-06-01), None
patent: WO 2005/074633 (2005-08-01), None
patent: WO 2006/110581 (2006-10-01), None
patent: WO 2008/051797 (2008-05-01), None
patent: WO 2008/057144 (2008-05-01), None
patent: WO 2008/076960 (2008-06-01), None
patent: WO 2008/091641 (2008-07-01), None
patent: WO 2008/108910 (2008-09-01), None
patent: WO 2008/136848 (2008-11-01), None
patent: WO 2009/025867 (2009-02-01), None
patent: WO 2009/035522 (2009-03-01), None
patent: WO 2010/005567 (2010-01-01), None
Duan et al. A novel Notch protein, N2N, targeted by neutrophil elastase and implicated in hereditary neutropenia. Mol Cell Biol 24(1): 58-70, 2004.
Santa Cruz Biotechnology datasheet for Notch2(25-255) antibody; downloaded on Dec. 2, 2009.
Huang et al. Surface expression of notch1 on thymocytes: correlation with the double-negative to double-positive transition. J Immunol 171: 2296-2304, 2003.
Al-Hajj et al., “Prospective Identification of Tumorigenic Breast Cancer Cells”, Cell Biology 100:3983-3988 (2003), Proceedings of the National Academy of Science, 700 11th Street, NW Suite 450 Washington, DC 20001.
Arias et al., “Csl-Independent Notch Signalling: A Checkpoint in Ceu Fate Decisions During Development?”, Current Opinion In Genetics & Development, 12:524-533 (2002), Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1 GB, UK.
Artavanis-Tsakonas et al., “Notch Signaling: Cell Fate Control and Signal Integration in Development”, Science 284:770 (1999), American Association for the Advancement of Science, 1200 New York Avenue, NW, Washington, DC 20005.
Brennan and Brown, “Is There a Role for Notch Signalling in Human Breast Cancer?”, Breast Cancer Research, 5:69 (2003), BioMed Central Ltd, London WC1X 8HL, United Kingdom.
Brennan et al., “Repression by Notch is Required Before Wingless Signalling During Muscle Progenitor Cell Development in Drosophila”, Current Biology, 9:707-710 (1991), Current Biology Publications, 34-42 Cleveland Street, London W1 P GLE, UK.
Cole et al., “The Ebv-Hybridoma Technique and its Application to Human Lung Cancer”, Monoclonal Antibodies and Cancer Therapy, 77-96 (1985), Alan R. Liss, Inc, 41 East 11th Street, New York, NY 10003.
Del Amo et al., “Cloning, Analysis, and Chromosomal Localization of Notch-1, a Mouse Homolog of Drospohila Notch,” Genomics, 15:259-264 (1993), Academic Press, Inc.
Domenga et al., “Notch3 is required for arterial identity and maturation of vascular smooth muscle cells,” Genes & Development, 18:2730-2735 (2004), Cold Spring Harbor Laboratory Press.
Duncan et al., “Integration of Notch and Wnt Signaling in Hematopoietic Stem Cell Maintenance”, Nature Immunology 6:314-322 (2005), Nature Publishing Group, 345 Park Avenue South, New York, NY 10010-1707.
Ellisen et al., “Tan-1, The Human Homolog of the Drosophila Notch Gene, Is Broken by Chromosomal Translocations in T Lymphoblastic Neoplasms”, Cell, 66:649-661 (1991), Cell Press, 50 Church Street, Cambridge, Massachusetts 02138.
Gale et al., “Haploinsufficiency of Delta-Like 4 Ligand Results in Embryonic Lethality Due to Major Defects in Arterial and Vascular Development”, PNAS, 101:15949-15954 (2004), National Academy of Science, 700 11th Street, NW Suite 450 Washington, DC 20001.
Gallahan et al., “Expression of a Truncated Int3 Gene in Developing Secretory Mammary Epithelium Specifically Retards Lobular Differentiation Resulting in Tumorigenesis”, Cancer Research, 56:1775-1785 (1996), American Association for Cancer Research, Inc, Public Ledger Bldg., Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483.
Gridley, T., “Notch signaling and inherited disease syndromes,” Human Molecular Genetics 12:R9-R13 (2003), Oxford University Press.
Gridley, T., “Notch signaling during vascular development,” PNAS, 98:5377-5378 (2001), National Academy of Sciences, Washington, DC 20001.
Gridley, T., “Vessel guidance,” Nature, 445:722-723 (2007) Nature Publishing Group, New York, NY 10013-1917, USA.
Gridley, T., “Notch Signaling in Vertebrate Development and Disease,” Mol. Cell. Neurosci, 9:103-108, (1997), Academic Press, 6277 Sea Harbor Drive, Orlando, FL 32887-4900.
Hadland et al., “A requirement for Notchl distinguishes 2 phases of definitive hematopoiesis during development,” Blood, 104:3097-3105 (2004), The American Society of Hematology.
Hainaud et al., “The Role of the Vascular Endothelial Growth Factor-Delta-like 4 Ligand/Notch4-Ephrin B2 Cascade in Tumor Vessel Remodeling and Endothelial Cell Functions,” Cancer Res, 66:8501-8510, (2006), American Association for Cancer Research.
Hallahan et al., “The SmoAl Mouse Model Reveals that Notch Signaling is Critical for the Growth and Survival of Sonic Hedgehog-Induced Medulloblastomas”, Cancer Research, 64:7794-7800 (2004), American Association for Cancer Research, Philadelphia, PA 19106-4404.
Hitoshi et al., “Notch Pathway Molecules are Essential for Tile Maintenance, but not the Generation of Mammalian Neural Stem Cells”, Genes & Development, 16:846-858 (2002), Cold Spring Harbor Laboratory Pres
Gurney Austin
Hoey Timothy
Lewicki John A.
Satyal Sanjeev
Yen Wan-Ching
Bunner Bridget E.
OncoMed Pharmaceuticals, Inc.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Antibodies to notch receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to notch receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to notch receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2638352